Search Results

Your search for Isabelle Ray-Coquard, MD, PhD, on Ovarian Cancer: Olaparib Plus Bevacizumab matches 1 pages

Showing 1 - 1

By The ASCO Post Staff / ESMO 2018 Congress / Tuesday, October 23, 2018 9:25 AM

ESMO 2018: SOLO-1: Olaparib Maintenance Extends Progression-Free Survival in BRCA1/2-Mutated Advanced Ovarian Cancer

Two-year maintenance therapy with olaparib (Lynparza), a poly ADP-ribose polymerase (PARP) inhibitor, led to a substantial improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation, results from the phase III SOLO-1 trial...

Apr

Today In Oncology

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer